Scinai Immunotherapeutics Ltd Total Liabilities
Scinai Immunotherapeutics Ltd total liabilities. Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has total liabilities worth $5.44 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scinai Immunotherapeutics Ltd (SCNI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scinai Immunotherapeutics Ltd (2000–2025)
Total liabilities of Scinai Immunotherapeutics Ltd from 2000 to 2025. This chart illustrates how Scinai Immunotherapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Scinai Immunotherapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dewhurst plc
LSE:DWHA
|
UK | GBX10.81 Million |
|
Sanco Industries Limited
NSE:SANCO
|
India | Rs687.89 Million |
|
Desarrolladora Homex S.A.B. de C.V
MX:HOMEX
|
Mexico | MX$1.00 Billion |
|
GO.D.M Investments Ltd
TA:GODM
|
Israel | ILA165.00K |
|
Arcadia Biosciences Inc
NASDAQ:RKDA
|
USA | $2.41 Million |
|
Windar Photonics Plc
LSE:WPHO
|
UK | GBX2.79 Million |
|
Rivalry Corp
V:RVLY
|
Canada | CA$25.62 Million |
|
Bezant Resources Plc
LSE:BZT
|
UK | GBX1.35 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Scinai Immunotherapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scinai Immunotherapeutics Ltd total assets.
Liquidity & Leverage Metrics
Scinai Immunotherapeutics Ltd Total Liabilities Ratios Explained
Scinai Immunotherapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scinai Immunotherapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scinai Immunotherapeutics Ltd (2000–2025)
The table below shows the annual total liabilities of Scinai Immunotherapeutics Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.52 Million | +1.50% |
| 2024-12-31 | $3.47 Million | -84.25% |
| 2023-12-31 | $22.04 Million | -23.54% |
| 2022-12-31 | $28.83 Million | -7.17% |
| 2021-12-31 | $31.05 Million | +39.58% |
| 2020-12-31 | $22.25 Million | -57.51% |
| 2019-12-31 | $52.36 Million | +42.86% |
| 2018-12-31 | $36.65 Million | +401.21% |
| 2017-12-31 | $7.31 Million | +526.88% |
| 2016-12-31 | $1.17 Million | -41.45% |
| 2015-12-31 | $1.99 Million | +313.95% |
| 2014-12-31 | $481.23K | -9.16% |
| 2013-12-31 | $529.76K | +94.35% |
| 2012-12-31 | $272.58K | -39.54% |
| 2011-12-31 | $450.86K | -39.24% |
| 2010-12-31 | $742.07K | +44.75% |
| 2009-12-31 | $512.67K | +159.22% |
| 2008-12-31 | $197.78K | -94.94% |
| 2007-12-31 | $3.91 Million | +1527.92% |
| 2006-12-31 | $240.00K | -62.67% |
| 2005-12-31 | $643.00K | -38.47% |
| 2004-12-31 | $1.04 Million | -41.85% |
| 2003-12-31 | $1.80 Million | +11.48% |
| 2002-12-31 | $1.61 Million | +32140.00% |
| 2001-12-31 | $5.00K | -81.48% |
| 2000-12-31 | $27.00K | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more